Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.72 |
| ▸ | TK2 | O00142 | 8/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659184 | 1.00 | PYGM (0.72) | PYGMTK2P2RY6 | |
| SCHEMBL16341964 | 1.00 | PYGM (0.72) | PYGMTK2P2RY6 | |
| SCHEMBL23804108 | 0.89 | PYGM (0.74) | PYGMTK2P2RY6 | |
| SCHEMBL16341101 | 0.88 | PYGM (0.68) | PYGMTK2 | |
| SCHEMBL7182936 | 0.87 | TK2 (0.67) | PYGMTK2 | |
| SCHEMBL22992480 | 0.87 | TK2 (0.67) | PYGMTK2 | |
| SCHEMBL20875706 | 0.87 | TK2 (0.67) | PYGMTK2 | |
| SCHEMBL22992424 | 0.87 | TK2 (0.67) | PYGMTK2 | |
| SCHEMBL62322 | 0.87 | TK2 (0.67) | PYGMTK2 | |
| SCHEMBL31685558 | 0.87 | PYGM (0.54) | PYGMTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11725205-B2 | Methods and polynucleotides for amplifying a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2023147565-A2 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | Opentrons LabWorks Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230046363-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-02-16 | — | — | US | disclosed |
| US-10669578-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-06-02 | — | — | US | disclosed |
| US-10570440-B2 | Method for modifying a template double stranded polynucleotide using a MuA transposase | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20200032248-A1 | METHOD | Oxford Nanopore Technologies Inc. (GB) | 2020-01-30 | — | — | US | disclosed |
| US-20190249231-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| EP-3207152-B1 | METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| EP-3108010-B1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-20170240955-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-08-24 | — | — | US | disclosed |
| US-20170067101-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9410189-B2 | Methods of preventing non-specific reactions of nucleotide sequences | CO-DIAGNOSTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20120045796-A1 | NUCLEIC ACID HOTSTART TECHNOLOGY | CO-DIAGNOSTICS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | PYGM 1111/4885TK2 114/4885P2RY6 259/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | PYGM 4697/4885TK2 609/4885P2RY6 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.